Eli Lilly Earnings & Forecasts

Eli Lilly (LLY) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Aug 5, 2026	$8.38	$6.01	39.4 %
Q1	Apr 30, 2026	$8.55	$6.85	24.8 %
Q4	Feb 4, 2026	$7.54	$6.96	8.33 %
Q3	Oct 30, 2025	$7.02	$5.96	17.8 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Aug 5, 2026	$22.97B	$20.44B	12.4 %
Q1	Apr 30, 2026	$19.80B	$17.78B	11.4 %
Q4	Feb 4, 2026	$19.30B	$17.91B	7.74 %
Q3	Oct 30, 2025	$17.60B	$16.05B	9.69 %

Eli Lilly Guidance

Eli Lilly (LLY)은 지난 8월 5, 2026에 fiscal year 2026의 실적 전망을 발표했습니다. 회사는 주당순이익을 $35.5 - $36.5 범위로 전망했으며, 이는 시장 컨센서스 EPS 추정치인 $36.12보다 높은 수치입니다. Eli Lilly는 또한 해당 기간의 매출을 $85B - $87B 범위로 전망했습니다.

이전 가이던스와 비교하여 Eli Lilly는 주당순이익(EPS) 전망치를 이전 범위인 유지됨에서 $35.5 - $37로 상향 조정했습니다. 매출 측면에서는 회사가 매출 전망치를 이전 범위인 상향 조정됨에서 $82B - $85B로 상향 조정했습니다.

Eli Lilly은 22과 11월 1, 2022 사이에 8월 5, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 12 times and lowered it 5 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$6.01	$6.85	$6.96	$5.96
Actual	$8.38	$8.55	$7.54	$7.02
Surprise	+39.4%	+24.8%	+8.33%	+17.8%
Revenue
Estimate	$20.44B	$17.78B	$17.91B	$16.05B
Actual	$22.97B	$19.80B	$19.30B	$17.60B
Surprise	+12.4%	+11.4%	+7.74%	+9.69%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$9.81	$10.07	$9.70	$10.40
Revenue
Consensus	$22.20B	$23.40B	—	—

More with Benzinga EdgeGet Access

Stock Market Today: S&P 500, Dow Futures Gain After Scott Bessent Signals Strait of Hormuz Deal With Iran in Sight— AMD, SpaceX, SanDisk in Focus (UPDATED)

Dow and S&P 500 indices hit new all-time highs, Treasury Sec. Bessent says Iran deal may reopen Strait of Hormuz.

Benzinga Neuro

Eli Lilly Narrows FY2026 Adj EPS Guidance from $35.50-$37.00 to $35.50-$36.50 vs $34.20 Est; Raises FY2026 Sales Guidance from $82.000B-$85.000B to $85.000B-$87.000B vs $85.446B Est

Eli Lilly (NYSE:LLY) narrows FY2026 Adj EPS guidance from $35.50-$37.00 to $35.50-$35.60 vs $34.20 analyst estimate. Raises FY2026 sales outlook from $82.000 billion-$85.000 billion to $85.000 billion-$87.000 billion vs

Benzinga News-desk

PRO
Eli Lilly Q2 Adj. EPS $8.38 Beats $6.01 Estimate, Sales $22.974B Beat $20.725B Estimate

Eli Lilly (NYSE:LLY) reported quarterly earnings of $8.38 per share which beat the analyst consensus estimate of $6.01 by 39.43 percent. This is a 32.81 percent increase over earnings of $6.31 per share from the same

Benzinga Newsdesk

Eli Lilly and Co